|
Match
|
Document |
Document Title |
|
|
7531551 |
Polymorphs of cabergoline
Provided are new crystalline Forms VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and...
|
|
|
7144843 |
Pest controllers
An objective of the present invention is to provide a harmful organism control agent that possesses excellent control effect against harmful organisms and can be safely used. The present invention...
|
|
|
7141582 |
Method for enhancing mutant enzyme activities in Gaucher disease
Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance...
|
|
|
7071234 |
Methods of treating or preventing erectile dysfunction
Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional...
|
|
|
6916829 |
Method for enhancing mutant enzyme activity in gaucher disease
Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance...
|
|
|
6849619 |
Substituted pyridoindoles as serotonin agonists and antagonists
The present invention is directed to certain novel compounds represented by structural Formula (I)
or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6 , R 7 , R 8 , R 9...
|
|
|
6844353 |
Fungicidal properties of sampangine and its analogs to agriculturally important fungal plant pathogens
It has been found that sampangine and related analogs such as benzo[4,5]sampangine, 4-bromosampangine and 4-methoxysampangine may be used as effective fungicidal agents for plants. Fungicidal plant...
|
|
|
6800635 |
Crystalline form II of cabergoline
Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw...
|
|
|
6777406 |
Substituted pyrroloquinolines and pyridoquinolines as serotinin agonists and antagonists
The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein is R 1 , R 6a , R 6b , R 7 , R 8 , R...
|
|
|
6777405 |
Detection and treatment of duplex polynucleotide damage
Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions...
|
|
|
6680327 |
Crystalline form VII of cabergoline
Crystalline form VII of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise a slurry procedure using form I or mixture...
|
|
|
6664263 |
1,8-naphthalimide imidazo&lcub 4,5,1-de&rcub acridones with anti-tumor activity
The invention provides imidazoacridone compounds of general formula (1) which have cytotoxic and anti-tumor activity. The invention also provides methods of preparing the compounds, and methods of...
|
|
|
6559161 |
Cytotoxic pyrido&lsqb 2,3,4-ki&rsqb acridine derivatives, their preparation and their therapeutic use
The invention provides compounds of formula (I) wherein R 1 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, a hydroxy group, an alkoxy group having from 1 to 6...
|
|
|
6555548 |
Compounds for treating fibromyalgia and chronic fatigue syndrome
The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of cabergoline-type compounds or a salt of said compound.
|
|
|
6545011 |
Substituted 4,9-dihydrocyclopenta&lsqb imn&rsqb phenanthridine-5-ones, derivatives thereof and their uses
This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
|
|
|
6503920 |
Cabergoline and pramipexole: new uses and combinations
This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of...
|
|
|
6492332 |
Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
This invention relates to a method of inhibiting tumor cell adhesion, pain, and inflammation at a wound during a surgical procedure by delivering an irrigation solution containing a tumor cell...
|
|
|
6476021 |
Compounds having cGMP-PDE inhibitory effect
Novel fused tetracyclic heterocyclic compounds having a potent and highly selective effect of inhibiting cyclic GMP phosphodiesterase (cGMP-PDE) and a high safety; a process for producing the same;...
|
|
|
6469019 |
Therapeutic application of nicergoline
The invention concerns the use of nicergoline for preventing and/or treating motor neuron diseases.
|
|
|
6403651 |
Mediation of circadian rhythms
Method for mediating the effects of light on melatonin rhythmicity in mammals and a method of mediating circadian rhythms, effected by the administration of a compound or compounds effective at a...
|
|
|
6380267 |
Composition and method for decreasing neurologic symptomatology
A method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a...
|
|
|
6380208 |
Use of nicergoline for treating spasticity
The invention concerns the use of nicergoline for treating pyramidal spasticity of neurological diseases involving a pathology of the cerebrospinal tract.
|
|
|
6358967 |
Ergoline amine derivatives with blood pressure lowering effect
The invention relates to novel derivatives of ergoline of the general formula 1 in which R 1 together with the two adjacent N atoms is the residue of a diamine and R 4 together with the two...
|
|
|
6346536 |
Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
Poly(ADP-ribose) polymerase (“PARP”) inhibitors and methods for treating neurodegenerative diseases, neural tissue damage related to cerebral ischemia and reperfusion injury, and cardiovascular...
|
|
|
6297254 |
Method for the prevention or treatment of a motoneuron disease
The present invention relates to a method for the prevention or treatment of a motoneuron disease with a combination of an ergoline chosen from nicergoline and lumilysergol and of riluzole or one...
|
|
|
6228864 |
Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
A method is provided for delaying the onset of ejaculation in an individual. The method preferably involves administration of an antidepressant drug, a serotonin agonist or antagonist, an...
|
|
|
6191132 |
Use of quisqualate receptor antagonists
The new use of antagonists of the AMPA receptor complex and its physiologically compatible salts as pharmaceutical agents for prevention and treatment of Parkinson's disease as well as...
|
|
|
6153645 |
Heterocycles as antimicrobial agents
Methods for treating infection and related compositions, compounds of formula I as defined in the application and methods for preparing same, are provided. In general, the compounds inhibit...
|
|
|
6136818 |
Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
A method of treating sexual dysfunction comprising administering a therapeutically effective amount of a combination of phentolamine and apomorphine, as well as pharmaceutical compositions and kits...
|
|
|
6114326 |
Use of cabergoline in the treatment of restless legs syndrome
The present invention provides for the use of cabergoline and other agents for the treatment of restless legs syndrome (RLS).
|
|
|
6075020 |
Method of regulating immune function
Disclosed herein is a method of treating an immune system dysfunction in a mammal by administering a prolactin reducer and a prolactin enhancer at a predetermined time or times.
|
|
|
6071914 |
Method for inhibiting neoplastic disease in mammals
This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a...
|
|
|
6060483 |
Antineurodegenerative ergoline derivatives
|
|
|
6043244 |
Method and composition for treating migraine
This invention relates to methods and compositions for the treatment of migraine headache by administering a combination of a) a migraine-treating amount of an ergot alkaloid and b) an...
|
|
|
6030984 |
Pyridone compounds useful in treating Alzheimer's disease
The invention is concerned with the use of bi- and tricyclic pyridone compounds of the formula where A, R 1 , R 3 , R 4 , and R 7 are described herein and of their pharmaceutically acceptable...
|
|
|
6004972 |
Therapeutic process for the treatment of the pathologies of type II diabetes
A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these...
|
|
|
6001848 |
Bromocriptine for the treatment of alcoholics diagnosed with the D.sub.2 dopamine receptor DRD2 A1 allele
Disclosed are dopamine agonist and opioidergic compositions and methods for their use in the treatment of alcoholism. The invention discloses compounds and therapeutic kits useful in the treatment...
|
|
|
5905083 |
Method of treating rheumatoid arthritis
Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems, such as rheumatoid arthritis. Also disclosed are methods for modifying normal responses of the...
|
|
|
5880134 |
Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT.sub.7 receptor
The present invention provides a method for altering mammalian central and peripheral physiological and pathological functioning which is mediated by serotonin binding to the 5-HT 7 receptor....
|
|
|
5877183 |
Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
Provided are methods for the regulation and modification of lipid and glucose metabolism by administering to a subject a dopamine D1 agonist, optionally in combination with a dopamine D2 agonist,...
|
|
|
5854255 |
Therapeutic package for the long term reduction of body fat stores insulin resistance hyperinsulinemia and hyperglycemia in vertebrates
A therapeutic package for dispensing to, or for use in dispensing to, a vertebrate being treated for a metabolic condition selected from the group consisting of obesity, insulin resistance,...
|
|
|
5830895 |
Methods for the determination and adjustment of prolactin daily rhythms
Methods for detecting abnormalities in prolactin daily rhythms of a subject are provided. Prolactin levels of a subject are compared to levels of healthy subjects and based on the comparison a...
|
|
|
5798363 |
Use for tachykinin antagonists to treat emesis
The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel...
|
|
|
5795575 |
Topical medicament which increases the number of capillaries in damaged skin
A method for increasing the number of capillaries in damaged skin during healing of the skin is disclosed. The method includes the application of a skin composition to the damaged skin which...
|
|
|
5760047 |
Method for treatment of obesity using prolactin modulators and diet
The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such...
|
|
|
5750519 |
Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being...
|
|
|
5739146 |
Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
The present invention provides (8β)-N-substituted cyclo or bicycloalkyl-6-(substituted)-ergoline-8-carboxamides useful for occupying 5HT 2 or 5HT 1<1unull>s receptors in mammals. The invention...
|
|
|
5719160 |
Method for modifying and regulating lipid metabolism
A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being...
|
|
|
5716962 |
Process for therapeutically modifying and resetting prolactin rhythm with a dopamine agonist
A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these...
|
|
|
5716957 |
Method for modifying and resetting the bloodstream prolactin levels of a human subject
A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being...
|